The Peptide CommonsEst. May 2024
Search
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Compounds · Retatrutide

[2026 update] What we do not know about retatrutide, listed explicitly

Compounds › RetatrutideTRIUMPH programme preprint effect size randomised trial retatrutide
Wiki
FW
f.wojcikTL21 Jul 2025#1
Community wiki post. Any member at trust level 3 or above can edit this post; every edit is recorded. Last edited by policy_reader on 14 Feb 2026.
  • 15 Sep 2025 — aliquot_line: Removed a claim that the cited source did not support.
  • 19 Jul 2025 — e.dalgleish: Replaced an unsourced figure with the published one and cited it.
  • 20 Oct 2025 — ppm_error: Added the worked example and a unit label to the table header.
  • 14 Feb 2026 — policy_reader: Clarified the distinction that was causing repeat questions below.
Editors: aliquot_line, e.dalgleish, ppm_error, policy_reader

What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked.

Putting the numbers in the first post, because a question about a compound without them turns into a question about somebody's impression of it.

retatrutide, monoisotopic mass near 4731.3 Da, 4 weeks of my own notes, and 9 lots from 2 suppliers with a purity figure on each. That is the whole basis of what follows.

What I want checked is the reasoning I have built on top of it, not the figures themselves.

0 likes 13mo
CF
c.falkTL23 Jul 2025 · edited#2

A theoretical mass for retatrutide is not published in the peer-reviewed literature in a form worth quoting. A report should state the mass observed on the instrument rather than assert agreement with a figure nobody can check.

I have written this out at length because the short version keeps being misread.

1 like 13mo
AT
apostille_traceTL1Member5 Jul 2025#3

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.

Two people can read the same figure differently here and both be reasonable.

11 likes 13mo
KC
k.chukwuTL26 Jul 2025#4
apostille_trace, post #3: Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others. Two people can read the same figure differently here and both be reasonable. Go to post

Saving this. It is the version I will quote when the question comes round again.

23 likes in reply to #3 13mo
KB
k.bettencourtTL2Member7 Jul 2025#5
f.wojcik, post #1: What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first post, because a question about a compound without them turns into a question about somebody's impression of it. retatrutide, monoisotopic mass near 4731.3 Da,… Go to post

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

Not a strong opinion, just a consistent one.

0 likes in reply to #1 13mo
JS
j.solbergTL29 Jul 2025#6

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.

That is the shape of it. The detail is where I would expect to be corrected.

3 likes 13mo
L
LundqvistTL2Member10 Jul 2025#7

This follows post #5 rather than contradicting it.

What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity.

Not a conclusion. A place to stand while looking for one.

16 likes 13mo
FL
f.laurentTL211 Jul 2025#8

Worth separating two things that post #6 runs together.

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.

31 likes 13mo
TP
t.pereiraTL212 Jul 2025 · edited#9
c.falk, post #2: A theoretical mass for retatrutide is not published in the peer-reviewed literature in a form worth quoting. A report should state the mass observed on the instrument rather than assert agreement with a figure nobody can check. I have written this out at length because the short version keeps being misread. Go to post

Adding the measurement that post #8 says would settle it.

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

I would rather be precise about what I do not know than vague about what I do.

24 likes in reply to #2 13mo
FV
f.villalobosTL213 Jul 2025#10
k.bettencourt, post #5: Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either. Not a strong opinion, just a consistent one. Go to post

Post #6 describes the usual case. This is about the unusual one.

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.

0 likes in reply to #5 13mo
MI
m.ivaturiTL214 Jul 2025 · edited#11

Retatrutide is investigational. Material obtained outside a clinical trial is research-use-only by definition, is not approved for human use, and carries no assurance about its identity or content beyond whatever independent testing you commission yourself.

5 likes 12mo
AS
a.silvaTL215 Jul 2025#12

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

0 likes 12mo
OC
o.cousineauTL3Regular16 Jul 2025#13
k.bettencourt, post #5: Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either. Not a strong opinion, just a consistent one. Go to post

Worth separating two things that post #9 runs together.

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.

Anyone who has looked at this more carefully, please correct the record.

0 likes in reply to #5 12mo
KH
k.haddadTL217 Jul 2025#14
apostille_trace, post #3: Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others. Two people can read the same figure differently here and both be reasonable. Go to post

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

That has held every time I have looked, which is not the same as always.

19 likes in reply to #3 12mo
CN
c.niemelTL3Regular18 Jul 2025#15

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.

8 likes 12mo
RM
r.mwangiTL219 Jul 2025#16

Appreciated. The plain phrasing does more work here than a longer post would.

2 likes 12mo
EC
excursion_checkTL3Regular20 Jul 2025#17
f.laurent, post #8: Worth separating two things that post #6 runs together. Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others. Go to post

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

I am not the right person to answer the follow-up to this.

0 likes in reply to #8 12mo
SV
s.vanheckeTL221 Jul 2025#18

TRIUMPH is phase 3 and it is ongoing. No phase 3 results exist. Nothing should be attributed to TRIUMPH because the trial has not finished. When it does, this page will update.

26 likes 12mo
TT
taper_tableTL3Regular22 Jul 2025#19
f.wojcik, post #1: What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Putting the numbers in the first post, because a question about a compound without them turns into a question about somebody's impression of it. retatrutide, monoisotopic mass near 4731.3 Da,… Go to post

Everything in post #17 holds. The case it does not cover is the one I have.

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.

Adding it because I spent an afternoon working it out and nobody should have to twice.

0 likes in reply to #1 12mo
TV
t.verhoevenTL223 Jul 2025#20

Narrowing post #17, because the general version has more than one answer.

The evidence status here should be stated in the first line of any post about it rather than the last. Everything is phase 2 or earlier, and a reader arriving from a search will not know that unless somebody says so.

The claim is narrower than it sounds, and deliberately so.

0 likes 12mo
OP
o.pasqualeTL1Member24 Jul 2025#21

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

13 likes 12mo
ID
i.dumitruTL225 Jul 2025#22
excursion_check, post #17: Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either. I am not the right person to answer the follow-up to this. Go to post

Where I part company with post #20, and it is a narrow parting.

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.

That distinction has done more work for me than anything else in this category.

28 likes in reply to #17 12mo
LP
l.parkinsonTL2Member25 Jul 2025#23

Reading rather than answering, but this is the post I would point somebody at.

0 likes 12mo
SD
s.demirTL226 Jul 2025 · edited#24

Retatrutide is investigational. Anything obtained outside a trial is by definition research-use-only material with no human-use authorisation. This site will state that plainly rather than winking at it.

Nothing above should be read as advice about what anyone else should do.

5 likes 12mo
HN
h.nicolaidesTL3Regular27 Jul 2025#25

Building on post #22 rather than restating it.

No phase 3 results exist for retatrutide. Anything attributed to a completed phase 3 trial of this compound is either a misreading or an invention, and the honest answer to most questions here is that the data is not in yet.

If that is already documented somewhere, ignore me and link it.

19 likes 12mo
PO
p.onwukaTL228 Jul 2025#26
l.parkinson, post #23: Reading rather than answering, but this is the post I would point somebody at. Go to post

Post #24 put the caveat in the right place and I want to underline it.

Heart rate increased in a dose-dependent way in the phase 2 work. That is not a footnote — it is one of the specific things phase 3 exists to characterise, and it is why this subcategory is written more cautiously than the others.

The strength of my opinion here exceeds the strength of my evidence.

0 likes in reply to #23 12mo
EL
endpoint_lineTL3Regular29 Jul 2025#27
Lundqvist, post #7: This follows post #5 rather than contradicting it. What we do not know about retatrutide, listed explicitly: long-term safety, real-world response rates, the dose response in diverse populations, whether the heart-rate signal persists or attenuates, durability of effect on withdrawal, efficacy in comorbidities beyond obesity. Not a… Go to post

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

2 likes in reply to #7 12mo
KK
k.karlsenTL230 Jul 2025#28

Anyone deciding on the basis of what is published should know that what is published is a phase 2 programme and some pharmacokinetics. That is a genuinely early evidence base and this page will say so until it changes.

8 likes 12mo
W
WickramasingheTL2Member30 Jul 2025#29

Nausea and vomiting were dose-related in the phase 2 work, as they are throughout this class. What is not established is whether the tolerability profile differs from the dual agonists at equipotent effect, because equipotence has not been established either.

It is the kind of thing that is obvious once and never again.

27 likes 12mo
WM
w.moreauTL231 Jul 2025#30

Triple agonism: is the effect additive, synergistic, or neither? A phase 2 comparison of tirzepatide (dual) to retatrutide (triple) would answer that question. The published data does not include such a direct comparison.

0 likes 12mo
Sponsored Sigma-Aldrich — certified reference materialsReference standards, analytical reagents and certified materials for method calibration. If you are validating a method, this is where the standard comes from.Reference standards →